Results from a post-hoc analysis of JAVELIN-Renal 101 in patients with advanced renal cell carcinoma (RCC) who had not had a prior nephrectomy were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.
The JAVELIN Renal 101 study demonstrated a significant improvement in progression-free survival with avelumab plus axitinib versus sunitinib in patients with previously untreated clear cell metastatic RCC. This effect was seen in patients irrespective of prior nephrectomy. The current paper reports findings from a post hoc analysis of 117 patients enrolled in JAVELIN Renal 101 with kidney tumours who had not had a nephrectomy.
The avelumab plus axitinib combination improved progression-free survival in patients who did not undergo nephrectomy versus sunitinib. This effect was seen in both the kidney tumours and the metastases. The median overall survival was not reached.